Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2013

View Archived Issues

RespiVert presents results for the novel PI3K-gamma/delta inhibitor

Researchers identify novel plasma miRNA biomarkers for the diagnosis and prognosis of AAAs

Pfizer designs approach to develop potent brain-specific PET tracers

Novel RNAi therapeutics presented by Gradalis

Calimmune presents preclinical results for its anti-HIV lentiviral vector gene therapy

Targacept reports commencement of phase IIb TC-5214 study

Atopix receives U.K. Biomedical Catalyst grant

Novel PARP-1 inhibitors created at IMPACT Therapeutics

GlaxoSmithKline acquires vaccine developer Okairos

New IRAK-4 inhibitors designed by Merck & Co.

NICE issues final draft guidance recommending selective dapagliflozin use

AbbVie introduces high-dose Creon capsules in U.S.

Beijing Drug Administration accepts Sinovac's filing for EV71 vaccine candidate

Array BioPharma patents novel GPR119 receptor agonists

Encouraging topline results seen in phase II ofatumumab study

Chinese researchers report new cancer therapeutics

Idenix begins phase II study of all-oral combination of simeprevir and samatasvir for HCV

Researchers at Eli Lilly disclose novel retinoid RAR-gamma receptor antagonists

Novan reports promising findings from phase I study of acne treatment

Phase II trial to evaluate Immunovaccine's DPX-Survivac in glioblastoma

SBIR grant awarded to Orphagen for the development of novel small molecules

NEOMED and AstraZeneca expand strategic partnership

BioMarin's applications for Vimizim accepted by both FDA and EMA

FDA lifts clinical hold on phase II study of PharmAthene's anthrax vaccine

Endo Pharmaceuticals receives complete response letter from FDA regarding Aveed NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...